Multicomponent Breathlessness and Physical Activity Intervention in People With Asthma Using a Digital Platform

NCT07421115 · tracked via the Priya Life Science Australia tracker

Sponsor

University of Newcastle, Australia

Phase

Not applicable

Started

2026-03-01

Last updated

2026-02-19

Condition(s) studied

Asthma (Diagnosis)Breathlessness

Investigational drug(s) / intervention(s)

Multicomponent digital self-management platformEnhanced usual care

Multicomponent digital self-management platform: Attend an in-person session with an respiratory nurse, focused on breathlessness and physical activity self-management; and be provided access to a digital self-management platform

Enhanced usual care: Enhanced usual asthma tertiary care

Study summary

Treating breathlessness could help people with asthma have fewer symptoms and be more physically active. People with asthma report that it is important to deal with breathlessness during physical activity programs, but past research hasn't focused on this need.

The investigators have developed a multicomponent digitally supported intervention targeting breathlessness and physical inactivity. This study will test whether the multicomponent digital supported intervention will help people with asthma. The main question the study aims to answer is:

Does the multicomponent digitally supported intervention improve quality of life?

Participants will:

* Be allocated to the intervention or usual care. Allocation to either group will be random (like tossing a coin).
* Attend study visits to complete an assessment involving questionnaires and measurements
* Receive telephone calls to ask questions about health
* Be invited to take part in an interview to have a conversation about thoughts on participating in the study
* Be asked to provide consent to collect information from Services Australia regarding use of health care services and medications

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Aged 18 years or older * Able to provide informed consent * Evidence of variable airflow limitation within the past 10-years to confirm asthma diagnosis * Meets diagnostic criteria for moderate, or severe asthma * Reports breathlessness impacting daily life physical activities (modified Medical Research Council \[mMRC\] dyspnoea score ≥1) within the past 1-week * Owns a smart device with internet access, which they are willing and able to use for the study duration Exclusion Criteria: * High dependence on medical care * Significant life-limiting comorbidity (\<12 months life expectancy) * Cognitive impairment, poor English language skills or significant untreated hearing impairment that prevents completion of data collection forms or understanding of verbal instructions * Current participation in any other clinical trial, or participation in another clinical trial within the 4-weeks preceding study entry.

Primary outcome measure(s)

Asthma Quality of Life Questionnaire (AQLQ) — 6-months
Items are rated on a 7-point Likert scale, with higher scores indicating better quality of life. A mean score across all items equally weighted is reported. The minimal clinically important difference has been estimated to be 0.5 units.

Trial sites (2)

Facility	City	Region	Status
John Hunter Hospital	New Lambton Heights	New South Wales
The Prince Charles Hospital	Chermside	Queensland

More University of Newcastle, Australia trials in Australia

ROADMAP Clinical Trial Recruiting

Other trials for the same condition

Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07421115 on ClinicalTrials.gov ↗ ← All trials in Australia